Allele burden expansion in JAK2 (V617F) and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Ng ZY, Cottin L, Demoy M, Paz DL, Orvain C, Lambert WC, Ianotto JC, Lippert E, Ross DM, Iarossi D, Khan A, Lock D, Truong C, Laribi K, Yang YF, Gagnon LL, Ugo V, Harrison CN, O'Sullivan J

Open source

DOI
10.1002/hem3.70460
Published
2026 Sep
Container
HemaSphere
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70460,
  title = {Allele burden expansion in JAK2 (V617F) and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.},
  author = {Ng ZY and Cottin L and Demoy M and Paz DL and Orvain C and Lambert WC and Ianotto JC and Lippert E and Ross DM and Iarossi D and Khan A and Lock D and Truong C and Laribi K and Yang YF and Gagnon LL and Ugo V and Harrison CN and O'Sullivan J},
  year = {2026},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70460},
  url = {https://doi.org/10.1002/hem3.70460}
}

RIS

TY  - JOUR
TI  - Allele burden expansion in JAK2 (V617F) and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.
AU  - Ng ZY
AU  - Cottin L
AU  - Demoy M
AU  - Paz DL
AU  - Orvain C
AU  - Lambert WC
AU  - Ianotto JC
AU  - Lippert E
AU  - Ross DM
AU  - Iarossi D
AU  - Khan A
AU  - Lock D
AU  - Truong C
AU  - Laribi K
AU  - Yang YF
AU  - Gagnon LL
AU  - Ugo V
AU  - Harrison CN
AU  - O'Sullivan J
PY  - 2026
JO  - HemaSphere
DO  - 10.1002/hem3.70460
UR  - https://doi.org/10.1002/hem3.70460
ER  - 

APA

ZY, N., L, C., M, D., DL, P., C, O., WC, L., JC, I., E, L., DM, R., D, I., A, K., D, L., C, T., K, L., YF, Y., LL, G., V, U., CN, H., & J, O. (2026). Allele burden expansion in JAK2 (V617F) and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.. HemaSphere. https://doi.org/10.1002/hem3.70460

Source records